Overview of China’s medical insurance reimbursement status and generic drug launch status of ivonib (ivitinib)

Ivonib (ivitinib) is a targeted therapy drug developed byAgios Pharmaceuticals, Inc. Since being approved in China in 2022, it has achieved remarkable results in the clinical application of IDH1-mutant acute myeloid leukemia (AML) and IDH1-mutant cholangiocarcinoma. Currently, the medical insurance and generic drug situation of this drug has received widespread attention, and this article will introduce it in detail.

First of all, judging from the current situation of medical insurance, Avonib has not yet been officially included in China’s medical insurance catalog. This situation means that patients need to bear all costs when using this drug, which undoubtedly increases the treatment burden for some patients with tight financial conditions. Although the medical insurance department is constantly evaluating the effectiveness, safety and economics of new drugs in order to include more drugs that are beneficial to patients in medical insurance, it is still unclear how long Ivonib will be covered by medical insurance. Therefore, patients must fully consider their own financial situation when formulating treatment plans.

Regarding the situation of generic drugs, with the expiration of the patent protection period of the original drug of ivonib, generic versions of the drug have appeared on the market. Generic drugs refer to drugs produced by other pharmaceutical companies after the patent protection period of the original drug expires, and their dosage form, dosage, route of administration and indications are the same as the original drug. The launch of this type of generic drugs provides patients with more choices, and also reduces drug prices and improves drug accessibility through market competition.

For example, Lucius Pharmaceuticals in Laos produces generic drugs of ivonib, which are relatively low-priced. A box of250mg*60 tablets sells for about more than 4,000 yuan. This price has obvious advantages over the original drug and has brought economic relief to many patients. However, when selecting and using generic drugs, patients should be cautious and ensure that they are purchased through formal channels to ensure the quality and safety of the drugs.

For patients who need to use ivonib, it is recommended to purchase the drug in the following ways:

1. Consult professional overseas medical institutions to obtain specific purchasing channels and price information about generic ivonib drugs.

2. Go directly to Lucius Pharmaceutical Factory in Laos to purchase medicines, but please pay attention to relevant visa and travel arrangements.

Overall, although ivonib has not yet been included in China's medical insurance list, the emergence of generic drugs has brought more choices and more economical treatment options to patients. When faced with this treatment decision, patients should fully understand drug-related information, and choose and use drugs rationally based on their own health conditions and doctor's recommendations to obtain therapeutic effects.